title: [Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
abstract: OBJECTIVE
  In hypercholesterolemic patients, we studied the relationships of plasma levels of LDLoxab with cardiovascular variables and its changes after treatment with atorvastatin.
  
  
  METHODS
  We studied, in 48 patients, the levels of LDLoxab, as well as lipid, oxidative stress and inflammatory biomarkers, at baseline and 24 weeks after treatment with 20mg of atorvastatin.
  
  
  RESULTS
  Baseline: a correlation was observed between LDLoxab and age (r= 0.41, P=.03), waist (r=0.38, P=.04) and C reactive protein (r= 0.46, P=.02), but not with other variables. Atorvastatin treatment did not decrease LDLoxab;(mU/mL, median [CI 95%]: baseline: 413 [187-1,196] and 24 weeks: 349 [101-1559]). The percentage change at week 24, was negatively correlated with age (r=-0.37, P=.03) but not with other variables.
  
  
  CONCLUSIONS
  In hypercholesterolemic subjects plasma LDLoxab levels were positively corelated with age, waist and C reactive protein. There were no changes in plasma levels of LDLoxab after treatment with atorvastatin, but the variation was associated with age, suggesting that the immunomodulatory actions may depend of this.
authors.affiliation: Unidad de Riesgo Vascular de Medicina Interna, Hospital San Pedro de Alcántara, Cáceres, España. jfsmt@unex.es
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: Sánchez Muñoz-Torrero
authors.forename: Leandro
authors.initials: L
authors.lastname: Crespo
authors.forename: Luis
authors.initials: L
authors.lastname: Fernández Pereira
authors.forename: Gema
authors.initials: G
authors.lastname: Pereira
authors.forename: Carmen
authors.initials: C
authors.lastname: Cámara
authors.forename: Alberto
authors.initials: A
authors.lastname: Costo
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000276:immunology; D000069059:Atorvastatin; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D007249:Inflammation; D015227:Lipid Peroxidation / Q000187:drug effects / Q000276:immunology*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D055105:Waist Circumference
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D001786:Blood Glucose; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008077:Lipoproteins, LDL; D011758:Pyrroles; C099252:oxidized low density lipoprotein; D002097:C-Reactive Protein; D000069059:Atorvastatin; D003404:Creatinine